15353-j-veluchamy

1 General introduction and Scope of this Thesis | 29 38. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. The New England journal of medicine (1985) 313 (23):1485-92. Epub 1985/12/05. doi: 10.1056/nejm198512053132327. PubMed PMID: 3903508. 39. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 8 (4):299-308. 40. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2011) 13 (1):98-107. doi: 10.3109/14653249.2010.515582. PubMed PMID: PMC3760671. 41. Minculescu L, Marquart HV, Friis LS, Petersen SL, Schiødt I, Ryder LP, et al. Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell–Replete Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation (2016) 22 (12):2187-93. doi: http:// dx.doi.org/10.1016/j.bbmt.2016.09.006. 42. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stemcell transplantation. Advances in immunology (2006) 90 :133-73. Epub 2006/05/30. doi: 10.1016/s0065-2776(06)90004-2. PubMed PMID: 16730263. 43. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood (2001) 98 (12):3192-204. Epub 2001/11/24. PubMed PMID: 11719354. 44. Antin JH. T-cell depletion in GVHD: less is more? Blood (2011) 117 (23):6061-2. doi: 10.1182/ blood-2011-04-348409. 45. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants. Science (2002) 295 (5562):2097-100. doi: 10.1126/science.1068440. 46. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation. Blood (1999) 94 (1):333-9. 47. Koepsell SA, Miller JS, McKenna Jr DH. Natural killer cells: a review of manufacturing and clinical utility. Transfusion (2013) 53 (2):404-10. doi: 10.1111/j.1537-2995.2012.03724.x. 48. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One (2011) 6 (6):e20740. Epub 2011/06/24. doi: 10.1371/journal.pone.0020740. PubMed PMID: 21698239; PubMed Central PMCID: PMCPmc3116834. 49. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy (2008) 10 (6):625-32. doi: 10.1080/14653240802301872.